GHRH

This brand name is authorized in Spain, United Kingdom

Active ingredients

The drug GHRH contains one active pharmaceutical ingredient (API):

1 Somatorelin
UNII XY920R6F5N - SOMATORELIN ACETATE

Somatorelin is normally synthesised in the hypothalamus and stimulates the secretion of growth hormone from the pituitary gland. Somatorelin physiologically increases plasma growth hormone levels.

Read about Somatorelin

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
GHRH Lyophilised powder for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
V04CD05 Somatorelin V Various → V04 Diagnostic agents → V04C Other diagnostic agents → V04CD Tests for pituitary function
Discover more medicines within V04CD05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: ES Centro de informaciรณn online de medicamentos de la AEMPS Identifier(s): 59109
Country: GB Medicines & Healthcare Products Regulatory Agency Identifier(s): 48503

ยฉ All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.